BJOG : an international journal of obstetrics and gynaecology · 2025
Obstetric and Neonatal Outcomes in Pregnancies From a Dedicated Cystic Fibrosis-Maternal Health Service: A Retrospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Scott Rebecca, Downes Amy, Weitnauer Ladina, Dobra Rebecca, Singh Natasha, Robinson Rachel, Diable Emily, Collins Saraha, Bowman Elaine, Tobin Thomas, Jones Andrew, Simmonds Nicholas, Felton Imogen
Аннотация
OBJECTIVE: A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF-Maternal Health service.
DESIGN: Retrospective data review from a CF-Maternal Health service between September 2020 and February 2025.
SETTING: A large adult-CF service in London, UK.
POPULATION OR SAMPLE: Pregnant fwCF attending the Royal Brompton Hospital CF Service.
METHODS: Review of CF-Maternal Health service data.
MAIN OUTCOME MEASURES: Maternal, obstetric and neonatal outcomes.
RESULTS: Fifty-three fwCF completed 67 pregnancies, with 69 infants born. There were no stillbirths, neonatal or maternal deaths. ETI-therapy was reported in 81% of pregnancies. In fwCF without CF-Diabetes, 57% developed gestational diabetes. Hospital admission to treat an infective pulmonary exacerbation was required in 31% of pregnancies. Forty-five percent of pregnancies delivered vaginally; 78% of babies were born at term. A major congenital abnormality was diagnosed in 4% of infants. Baseline lung-function correlated positively with birth-weight and gestation at birth.
CONCLUSIONS: FwCF have improved maternal, obstetric and neonatal outcomes since the introduction of ETI-therapy, within a dedicated CF-Maternal Health service.
DESIGN: Retrospective data review from a CF-Maternal Health service between September 2020 and February 2025.
SETTING: A large adult-CF service in London, UK.
POPULATION OR SAMPLE: Pregnant fwCF attending the Royal Brompton Hospital CF Service.
METHODS: Review of CF-Maternal Health service data.
MAIN OUTCOME MEASURES: Maternal, obstetric and neonatal outcomes.
RESULTS: Fifty-three fwCF completed 67 pregnancies, with 69 infants born. There were no stillbirths, neonatal or maternal deaths. ETI-therapy was reported in 81% of pregnancies. In fwCF without CF-Diabetes, 57% developed gestational diabetes. Hospital admission to treat an infective pulmonary exacerbation was required in 31% of pregnancies. Forty-five percent of pregnancies delivered vaginally; 78% of babies were born at term. A major congenital abnormality was diagnosed in 4% of infants. Baseline lung-function correlated positively with birth-weight and gestation at birth.
CONCLUSIONS: FwCF have improved maternal, obstetric and neonatal outcomes since the introduction of ETI-therapy, within a dedicated CF-Maternal Health service.